At the news
? BEARISHIMPACT 6/10 424B5 filed Apr 6, 2026 at 16:11 ET
Oncolytics Biotech is conducting an at-the-market offering of up to $75 million in common stock through Jefferies, following a $250 million shelf registration. The company plans to use the proceeds for clinical development of pelareorep and general corporate purposes. This offering follows a recent shelf registration and represents potential future dilution.
- Oncolytics Biotech is offering up to $75 million in common stock through an at-the-market offering with Jefferies
- The offering is part of a $250 million shelf registration filed on April 1, 2026
- Proceeds will fund clinical development of pelareorep, research and development, operating costs, and general corporate purposes
- The offering price is up to $0.96 per share, with an expected issuance of up to 78,125,000 shares
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access